Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 07
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Ovid Therapeutics Inc
OVID
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.37
0.03
1.28%
Ult. Agg.: Oct 6, 4:59 PM
$2.41
0.07
2.99%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Ovid Therapeutics Financials
Ovid Therapeutics (OVID) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share
Benzinga Newsdesk
PRO
Ovid Therapeutics Q1 EPS $(0.12) Misses $(0.11) Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 14.29 percent increase over losses of $(0.14) per share
Benzinga Newsdesk
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally
Ovid Therapeutics shares climb after positive epilepsy data, new trial launch, and $60 million funding boost extending runway into 2028.
Vandana Singh
Earnings Scheduled For March 18, 2026
Benzinga Insights
PRO
Ovid Therapeutics Q4 EPS $0.06 Beats $(0.11) Estimate, Sales $718.000K Beat $13.333K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.11) by 152.63 percent. This is a 146.15 percent increase over losses of $(0.13) per share
Benzinga Newsdesk
PRO
Ovid Therapeutics Q3 EPS $(0.17) Misses $(0.15) Estimate, Sales $132.000K Beat $131.429K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 15.65 percent. This is a 15 percent increase over losses of $(0.20) per share from
Benzinga Newsdesk
